RecruitingPhase 2NCT04501718

Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children

Studying Medulloblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Sanbo Brain Hospital
Intervention
Apatinib Combined With Temozolomide and Etoposide Capsules(drug)
Enrollment
44 target
Eligibility
2-21 years · All sexes
Timeline
2020 – 2025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04501718 on ClinicalTrials.gov

Other trials for Medulloblastoma

Additional recruiting or active studies for the same condition.

See all trials for Medulloblastoma →

← Back to all trials